RESUMEN
Both obesity rates and antidepressant use have escalated in the last 20 years. Most people who start antidepressant treatment discontinue it on their own. Meanwhile, obesity rates continue to increase. To test the hypothesis that antidepressant use is a risk factor for obesity, even after long-term discontinuation, we developed a novel animal paradigm consisting of short-term exposure to stress and antidepressants, followed by long-term high-fat diet. We show here that recurrent restraint stress (RRS)-related weight loss is recovered 2 weeks after the end of stress in young growing rats receiving a high-fat diet. It is noteworthy that animals that received short-term antidepressant treatment with either imipramine or fluoxetine during 7 days of RRS showed behavioral evidence of antidepressant effects. When exposed to a high-fat diet after stress and when antidepressant treatment had ended, the animals had significant increases in caloric intake, body weight (BW) and size from 17 to 22 weeks following antidepressant discontinuation when compared with (control) RRS animals treated with saline and fed with a high-fat diet. These data are consistent with the previously described phenomenon of time-dependent sensitization, and support the notion that enduring effects of short-term antidepressant treatment become manifest on a long-term basis after antidepressant discontinuation, during conditions of high stress followed by high-fat intake. Analyses of open field and body size measurements obtained in a small subset of animals show that animals previously exposed to antidepressant had no deficits in locomotor activity and were larger. Antidepressant exposure may therefore be a covert, insidious and enduring risk factor for obesity, even after discontinuation of antidepressant treatment. Our data support the concept of persistent, long-term effects of pharmacological-environment interactions on BW regulation.
Asunto(s)
Antidepresivos/efectos adversos , Peso Corporal/efectos de los fármacos , Ambiente , Animales , Grasas de la Dieta/efectos adversos , Modelos Animales de Enfermedad , Ingestión de Alimentos/efectos de los fármacos , Ingestión de Energía/efectos de los fármacos , Modelos Lineales , Estudios Longitudinales , Masculino , Actividad Motora/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Restricción Física/efectos adversos , Estadísticas no Paramétricas , Estrés Psicológico/tratamiento farmacológico , Factores de Tiempo , Resultado del TratamientoRESUMEN
CONTEXT: High doses of (131)I are usually needed in the treatment of multinodular goitre (MNG) for effective thyroid volume (TV) reduction. Recombinant human thyroid-stimulating hormone (rhTSH) is an adjuvant to enhance (131)I uptake, allowing a decrease in radiation activity and enhancing (131)I efficacy. OBJECTIVE: To evaluate whether rhTSH increases the efficacy of a fixed activity of (131)I for the treatment of MNG. DESIGN: Two-year, observational, placebo-controlled study. SETTING: Patients received 0.1 mg rhTSH (A), 0.005 mg rhTSH (B) or placebo (C). A fixed activity of 1.11 GBq of (131)I was administered 24 h after rhTSH or placebo. PATIENTS: A total of 28 outpatients (26 females and two males) with MNG. MEASUREMENTS: TSH, free T4, T3, thyroglobulin (Tg) and TV. RESULTS: Basal radioactive iodine uptake and TV values were comparable among all groups. After rhTSH or placebo, peak levels of TSH, free T4, T3 and Tg were higher in A than in B or in C (p < 0.05). Hyperthyroidism was observed in A (n = 2), B (n = 6) and C (n = 4). Thyroid enlargement was reported in A (n = 3) and B (n = 6). After 24 months, 10 patients developed hypothyroidism (four in A, three in B and three in C). TV reduction was similar between A and B (37.2 +/- 25.5% vs. 39.3 +/- 27.9%, p = 0.88), but different from the non-significant reduction in C (15.3 +/- 28.3%, p = 0.08). CONCLUSIONS: Followed by 1.11 GBq, a very low dose of 0.005 mg rhTSH was equally safe and effective as 0.1 mg rhTSH. Both doses increased the efficacy of radioiodine. Adverse events were mild, transient and readily treatable.
Asunto(s)
Bocio Nodular/terapia , Radioisótopos de Yodo/uso terapéutico , Tirotropina/uso terapéutico , Anciano , Terapia Combinada , Relación Dosis-Respuesta en la Radiación , Femenino , Humanos , Radioisótopos de Yodo/efectos adversos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/uso terapéutico , Tirotropina/efectos adversos , Resultado del TratamientoAsunto(s)
Enfermedades Cardiovasculares/inmunología , Leptina/análogos & derivados , Leptina/deficiencia , Obesidad/complicaciones , Obesidad/tratamiento farmacológico , Adulto , Enfermedades Cardiovasculares/epidemiología , Femenino , Humanos , Mediadores de Inflamación/sangre , Leptina/uso terapéutico , Masculino , Obesidad/inmunología , Obesidad/metabolismo , Factores de RiesgoAsunto(s)
Leptina/farmacología , Metabolismo de los Lípidos/efectos de los fármacos , Adulto , Ácidos Grasos no Esterificados/sangre , Femenino , Terapia de Reemplazo de Hormonas , Humanos , Hiperinsulinismo/sangre , Leptina/deficiencia , Leptina/genética , Modelos Lineales , Masculino , Mutación Missense , Proteínas Recombinantes/farmacología , Aumento de Peso/efectos de los fármacosAsunto(s)
Bocio Nodular/tratamiento farmacológico , Bocio Nodular/radioterapia , Radioisótopos de Yodo/uso terapéutico , Glándula Tiroides/patología , Glándula Tiroides/fisiopatología , Tirotropina/uso terapéutico , Terapia Combinada , Estudios de Seguimiento , Bocio Nodular/patología , Bocio Nodular/fisiopatología , Humanos , Tamaño de los Órganos/efectos de los fármacos , Tamaño de los Órganos/efectos de la radiación , Ensayos Clínicos Controlados Aleatorios como Asunto , Proteínas Recombinantes/uso terapéutico , Glándula Tiroides/efectos de los fármacos , Glándula Tiroides/efectos de la radiación , Resultado del TratamientoRESUMEN
Recombinant human thyroid-stimulating hormone (rhTSH) enhances 131I uptake, permitting a decrease in radiation for the treatment of multinodular goiter (MNG). Our objective was to evaluate the safety and efficacy of a single 0.1-mg dose of rhTSH, followed by 30 mCi 131I, in patients with MNG. Seventeen patients (15 females, 59.0 ± 13.1 years), who had never been submitted to 131I therapy, received a single 0.1-mg injection of rhTSH followed by 30 mCi 131I on the next day. Mean basal thyroid volume measured by computed tomography was 106.1 ± 64.4 mL. 131I 24-h uptake, TSH, free-T4, T3, thyroglobulin, anti-thyroid antibodies, and thyroid volume were evaluated at regular intervals of 12 months. Mean 131I 24-h uptake increased from 18.1 ± 9.7 to 49.6 ± 13.4 percent (P < 0.001), a median 2.6-fold increase (1.2 to 9.2). Peak hormonal levels were 10.86 ± 5.44 mU/L for TSH (a median 15.5-fold increase), 1.80 ± 0.48 ng/dL for free-T4, 204.61 ± 58.37 ng/dL for T3, and a median of 557.0 ng/mL for thyroglobulin. The adverse effects observed were hyperthyroidism (17.6 percent), painful thyroiditis (29.4 percent) and hypothyroidism (52.9 percent). Thyroid volume was reduced by 34.3 ± 14.3 percent after 6 months (P < 0.001) and by 46.0 ± 14.6 percent after 1 year (P < 0.001). Treatment of MNG with a single 0.1-mg dose of rhTSH, followed by a fixed amount of radioactivity of 131I, leads to an efficacious decrease in thyroid volume for the majority of the patients, with a moderate incidence of non-serious and readily treatable adverse effects.
Asunto(s)
Femenino , Humanos , Masculino , Persona de Mediana Edad , Bocio Nodular/radioterapia , Radioisótopos de Yodo/administración & dosificación , Tirotropina/administración & dosificación , Terapia Combinada , Estudios de Seguimiento , Bocio Nodular/tratamiento farmacológico , Proteínas Recombinantes/administración & dosificación , Resultado del TratamientoRESUMEN
Recombinant human thyroid-stimulating hormone (rhTSH) enhances 131I uptake, permitting a decrease in radiation for the treatment of multinodular goiter (MNG). Our objective was to evaluate the safety and efficacy of a single 0.1-mg dose of rhTSH, followed by 30 mCi 131I, in patients with MNG. Seventeen patients (15 females, 59.0 +/- 13.1 years), who had never been submitted to 131I therapy, received a single 0.1-mg injection of rhTSH followed by 30 mCi 131I on the next day. Mean basal thyroid volume measured by computed tomography was 106.1 +/- 64.4 mL. 131I 24-h uptake, TSH, free-T4, T3, thyroglobulin, anti-thyroid antibodies, and thyroid volume were evaluated at regular intervals of 12 months. Mean 131I 24-h uptake increased from 18.1 +/- 9.7 to 49.6 +/- 13.4% (P < 0.001), a median 2.6-fold increase (1.2 to 9.2). Peak hormonal levels were 10.86 +/- 5.44 mU/L for TSH (a median 15.5-fold increase), 1.80 +/- 0.48 ng/dL for free-T4, 204.61 +/- 58.37 ng/dL for T3, and a median of 557.0 ng/mL for thyroglobulin. The adverse effects observed were hyperthyroidism (17.6%), painful thyroiditis (29.4%) and hypothyroidism (52.9%). Thyroid volume was reduced by 34.3 +/- 14.3% after 6 months (P < 0.001) and by 46.0 +/- 14.6% after 1 year (P < 0.001). Treatment of MNG with a single 0.1-mg dose of rhTSH, followed by a fixed amount of radioactivity of 131I, leads to an efficacious decrease in thyroid volume for the majority of the patients, with a moderate incidence of non-serious and readily treatable adverse effects.
Asunto(s)
Bocio Nodular/radioterapia , Radioisótopos de Yodo/administración & dosificación , Tirotropina/administración & dosificación , Terapia Combinada , Femenino , Estudios de Seguimiento , Bocio Nodular/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/administración & dosificación , Resultado del TratamientoRESUMEN
BACKGROUND: Alcoholism is seldom detected among emergency room outpatients, which is attributed to the non-adoption of diagnostic routines, to the difficulty of doing a special anamnesis for diagnosing alcoholism, and to the lack of sensitivity and specificity of the laboratory tests. This study has the purpose to determine whether the CAGE assay (composed by 4 questions of easy memorization) is able to supply this difficulty in detecting alcoholism. MATERIAL AND METHODS: We did a transversal study with consecutive sampling among outpatients of the Internal Medicine Department at Cajuru University Hospital emergency room. They were submitted to a standardized interview constituted by the CAGE and the CIDI assays (Composite International Diagnostic Interview, "demographics" and "disorders resulting from the use of alcohol" sections). From the sample obtained (n=374), we correlated the prevalence of alcoholism according to both questionnaires, considering the CIDI (DSM-IV criteria) to be the gold standard. RESULTS: The prevalence of alcohol dependence according to the DSM-IV criteria was 15.77%. We verified that the CAGE has 84.74% of sensitivity and 73.33% of specificity, with a cut point of 2 positive responses. CONCLUSIONS: We concluded that the CAGE is an instrument of easy application and good sensitivity and specificity when used at the emergency room, being able to supply the difficulties of alcoholism detection. We suggest that the CAGE be adapted as a routine at emergency rooms, increasing the alcoholism detection rate.
Asunto(s)
Alcoholismo/diagnóstico , Servicio de Urgencia en Hospital , Encuestas y Cuestionarios , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Sensibilidad y EspecificidadRESUMEN
OBJETIVO: Determinar se o questionário CAGE (composto por quatro perguntas de fácil memorizaçäo) é capaz de suprir a dificuldade de detecçäo do alcoolismo. MATERIAL E METODO: Realizamos um estudo transversal com amostragem consecutiva em pacientes da Clínica Médica do pronto-socorro do Hospital Universitário Cajuru, os quais foram submetidos a uma entrevista padronizada constituída pelo questionário CAGE e pelo CIDI (Composite International Diagnostic Interview, seções "demografia" e "desordens resultantes do uso de ßlcool"). Da amostra obtida (n=374), correlacionamos a prevalência de alcoolismo segundo ambos os questionários, considerando o CIDI (critérios do DSM-IV) como sendo o padräo-ouro. RESULTADOS: A prevalência de dependência de álcool segundo os critérios do DSM-IV foi de 15,77 por cento. Nós verificamos que o CAGE possui sensibilidade igual a 84,74 por cento e especificidade igual a 73,33 por cento para um ponto de corte igual a duas respostas afirmativas. Conclusöes: Concluímos que o questionário CAGE é um instrumento de fácil aplicaçäo e boa sensibilidade e especificidade quando usado no ambiente de pronto-socorro, podendo suprir as dificuldades de detecçäo do alcoolismo. Sugerimos que o questionário CAGE seja adotado como rotina no pronto-socorro, permitindo que o Ýndice de detecçäo de alcoolismo aumente